HLB Co., Ltd.

028300 · XKRX · Biotechnology · South Korea

Market Capitalization6.65T KRW

Trailing P/E-71.73 KRW

52-Week Change-42.38 KRW

Forward Annual Dividend Yield0.05%

Beta0.4150 KRW

HLB Co., Ltd. manufactures and constructs lifeboats and glass fiber pipes in South Korea and internationally. It engages in the repair and inspection of lifeboats; fabrication and installation of pipes; development and manufacturing of biopharmaceuticals products, such as anti-cancer drugs; and manufacture and sale of medical devices, as well as manufacture and sale of quasi-drugs products, including alcohol swabs, sampling tools, etc. The company is also involved in e-commerce, investment, and financing activities. Additionally, it develops biological drugs with MoA to infectious diseases. HLB Co., Ltd. was founded in 1975 and is headquartered in Ulsan, South Korea.

Industry

Biotechnology

Healthcare sector · South Korea

Stories

Structural patterns identified in HLB Co., Ltd.

No stories identified yet.

Key Metrics

Market Capitalization

6.65TKRW

AboveNormalMar 18, 2026

Trailing P/E

-71.73KRW

ExtremeMar 18, 2026

Revenue (TTM)

80.73BKRW

NormalMar 18, 2026

Coordination

Placeholder CorpCoordination

Example HoldingsCoordination

Sample IncCoordination

Supply Chain

Vaccine Supply Chain

The vaccine supply chain is shaped by three structural constraints that most manufacturing industries never encounter: cold chain integrity requires unbroken refrigeration from manufacturing to injection — with some products requiring ultra-cold storage at -70°C, biological manufacturing variability means vaccines are grown in living systems where yields fluctuate batch to batch and cannot be precisely controlled, and regulatory lot release requires every batch to be independently tested and approved before distribution — a process that takes weeks and cannot be skipped or parallelized.